FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2289872081> ?p ?o ?g. }

• W2289872081 endingPage "190" @default.
• W2289872081 startingPage "1" @default.
• W2289872081 abstract "Background Unprovoked first venous thromboembolism (VTE) is defined as VTE in the absence of a temporary provoking factor such as surgery, immobility and other temporary factors. Recurrent VTE in unprovoked patients is highly prevalent, but easily preventable with oral anticoagulant (OAC) therapy. The unprovoked population is highly heterogeneous in terms of risk of recurrent VTE. Objectives The first aim of the project is to review existing prognostic models which stratify individuals by their recurrence risk, therefore potentially allowing tailored treatment strategies. The second aim is to enhance the existing research in this field, by developing and externally validating a new prognostic model for individual risk prediction, using a pooled database containing individual patient data (IPD) from several studies. The final aim is to assess the economic cost-effectiveness of the proposed prognostic model if it is used as a decision rule for resuming OAC therapy, compared with current standard treatment strategies. Methods Standard systematic review methodology was used to identify relevant prognostic model development, validation and cost-effectiveness studies. Bibliographic databases (including MEDLINE, EMBASE and The Cochrane Library) were searched using terms relating to the clinical area and prognosis. Reviewing was undertaken by two reviewers independently using pre-defined criteria. Included full-text articles were data extracted and quality assessed. Critical appraisal of included full texts was undertaken and comparisons made of model performance. A prognostic model was developed using IPD from the pooled database of seven trials. A novel internal–external cross-validation (IECV) approach was used to develop and validate a prognostic model, with external validation undertaken in each of the trials iteratively. Given good performance in the IECV approach, a final model was developed using all trials data. A Markov patient-level simulation was used to consider the economic cost-effectiveness of using a decision rule (based on the prognostic model) to decide on resumption of OAC therapy (or not). Results Three full-text articles were identified by the systematic review. Critical appraisal identified methodological and applicability issues; in particular, all three existing models did not have external validation. To address this, new prognostic models were sought with external validation. Two potential models were considered: one for use at cessation of therapy (pre D-dimer), and one for use after cessation of therapy (post D-dimer). Model performance measured in the external validation trials showed strong calibration performance for both models. The post D-dimer model performed substantially better in terms of discrimination ( c = 0.69), better separating high- and low-risk patients. The economic evaluation identified that a decision rule based on the final post D-dimer model may be cost-effective for patients with predicted risk of recurrence of over 8% annually; this suggests continued therapy for patients with predicted risks ≥ 8% and cessation of therapy otherwise. Conclusions The post D-dimer model performed strongly and could be useful to predict individuals’ risk of recurrence at any time up to 2–3 years, thereby aiding patient counselling and treatment decisions. A decision rule using this model may be cost-effective for informing clinical judgement and patient opinion in treatment decisions. Further research may investigate new predictors to enhance model performance and aim to further externally validate to confirm performance in new, non-trial populations. Finally, it is essential that further research is conducted to develop a model predicting bleeding risk on therapy, to manage the balance between the risks of recurrence and bleeding. Study registration This study is registered as PROSPERO CRD42013003494. Funding The National Institute for Health Research Health Technology Assessment programme." @default.
• W2289872081 created "2016-06-24" @default.
• W2289872081 creator A5009368181 @default.
• W2289872081 creator A5015107938 @default.
• W2289872081 creator A5040942978 @default.
• W2289872081 creator A5047963230 @default.
• W2289872081 creator A5049252097 @default.
• W2289872081 creator A5051537242 @default.
• W2289872081 creator A5059773134 @default.
• W2289872081 creator A5091521597 @default.
• W2289872081 date "2016-02-01" @default.
• W2289872081 modified "2023-10-12" @default.
• W2289872081 title "Prediction of risk of recurrence of venous thromboembolism following treatment for a first unprovoked venous thromboembolism: systematic review, prognostic model and clinical decision rule, and economic evaluation" @default.
• W2289872081 cites W1498499345 @default.
• W2289872081 cites W1524501969 @default.
• W2289872081 cites W1543389126 @default.
• W2289872081 cites W1573523596 @default.
• W2289872081 cites W1590642849 @default.
• W2289872081 cites W1777100975 @default.
• W2289872081 cites W1932917387 @default.
• W2289872081 cites W1937874266 @default.
• W2289872081 cites W1968393224 @default.
• W2289872081 cites W1969298821 @default.
• W2289872081 cites W1969579134 @default.
• W2289872081 cites W1973914781 @default.
• W2289872081 cites W1976812315 @default.
• W2289872081 cites W1977764501 @default.
• W2289872081 cites W1983782921 @default.
• W2289872081 cites W1985299015 @default.
• W2289872081 cites W1990005059 @default.
• W2289872081 cites W2001497857 @default.
• W2289872081 cites W2003601153 @default.
• W2289872081 cites W2004864119 @default.
• W2289872081 cites W2014569258 @default.
• W2289872081 cites W2022713742 @default.
• W2289872081 cites W2028896946 @default.
• W2289872081 cites W2031127066 @default.
• W2289872081 cites W2037668591 @default.
• W2289872081 cites W2038826213 @default.
• W2289872081 cites W2047986798 @default.
• W2289872081 cites W2052282840 @default.
• W2289872081 cites W2058948365 @default.
• W2289872081 cites W2060513754 @default.
• W2289872081 cites W2060932845 @default.
• W2289872081 cites W2064357176 @default.
• W2289872081 cites W2065974896 @default.
• W2289872081 cites W2066157763 @default.
• W2289872081 cites W2072886936 @default.
• W2289872081 cites W2073700468 @default.
• W2289872081 cites W2074703669 @default.
• W2289872081 cites W2081202263 @default.
• W2289872081 cites W2082315647 @default.
• W2289872081 cites W2082376914 @default.
• W2289872081 cites W2084139018 @default.
• W2289872081 cites W2085797065 @default.
• W2289872081 cites W2091682083 @default.
• W2289872081 cites W2100741073 @default.
• W2289872081 cites W2107328434 @default.
• W2289872081 cites W2108116635 @default.
• W2289872081 cites W2110032017 @default.
• W2289872081 cites W2110078301 @default.
• W2289872081 cites W2110891636 @default.
• W2289872081 cites W2113530759 @default.
• W2289872081 cites W2113801012 @default.
• W2289872081 cites W2117966469 @default.
• W2289872081 cites W2118502261 @default.
• W2289872081 cites W2119910794 @default.
• W2289872081 cites W2131099415 @default.
• W2289872081 cites W2134843796 @default.
• W2289872081 cites W2135369095 @default.
• W2289872081 cites W2136085913 @default.
• W2289872081 cites W2144714162 @default.
• W2289872081 cites W2146954532 @default.
• W2289872081 cites W2149429834 @default.
• W2289872081 cites W2158196600 @default.
• W2289872081 cites W2162491525 @default.
• W2289872081 cites W2166361233 @default.
• W2289872081 cites W2166456531 @default.
• W2289872081 cites W2168051713 @default.
• W2289872081 cites W2170004313 @default.
• W2289872081 cites W2170346040 @default.
• W2289872081 cites W2271427560 @default.
• W2289872081 cites W2323559086 @default.
• W2289872081 cites W2480680997 @default.
• W2289872081 cites W2494169975 @default.
• W2289872081 cites W2576440140 @default.
• W2289872081 cites W2963500787 @default.
• W2289872081 cites W2979589483 @default.
• W2289872081 cites W3175417087 @default.
• W2289872081 cites W4213286494 @default.
• W2289872081 cites W4251831579 @default.
• W2289872081 doi "https://doi.org/10.3310/hta20120" @default.
• W2289872081 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4781504" @default.
• W2289872081 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26879848" @default.
• W2289872081 hasPublicationYear "2016" @default.
• W2289872081 type Work @default.
• W2289872081 sameAs 2289872081 @default.
• W2289872081 citedByCount "27" @default.

• next